PROMIS NEUROSCIENCES INC. Research and Development Expense
PROMIS NEUROSCIENCES INC. (PMN) reported Research and Development Expense of $9.52 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- PROMIS NEUROSCIENCES INC. research and development expense for the quarter ending 2026-06-30 was $9.52M, a 8.82% increase year-over-year.
- PROMIS NEUROSCIENCES INC. research and development expense for the quarter ending 2026-03-31 was $6.97M, a 27.57% increase year-over-year.
- PROMIS NEUROSCIENCES INC. research and development expense for the quarter ending 2025-12-31 was $9.37M, a 116.62% increase year-over-year.
- PROMIS NEUROSCIENCES INC. research and development expense for the quarter ending 2025-09-30 was $9.80M, a 282.15% increase year-over-year.
- PROMIS NEUROSCIENCES INC. research and development expense for fiscal 2025 was $33.38M, a 213.78% increase from fiscal 2024.
- PROMIS NEUROSCIENCES INC. research and development expense for fiscal 2024 was $10.64M, a 34.95% increase from fiscal 2023.
- PROMIS NEUROSCIENCES INC. research and development expense for fiscal 2023 was $7.88M, a 51.00% decline from fiscal 2022.
- PROMIS NEUROSCIENCES INC. research and development expense for fiscal 2022 was $16.09M, a 247.65% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.52M 10-Q · filed 2026-08-13 | $16.49M 10-Q · filed 2026-08-13 | $25.86M derived: sum of 3 quarters · filed 2026-08-13 | $35.66M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $6.97M 10-Q · filed 2026-05-12 | $16.34M derived: sum of 2 quarters · filed 2026-05-12 | $26.14M derived: sum of 3 quarters · filed 2026-05-12 | $34.89M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $9.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $19.17M derived: sum of 2 quarters · filed 2026-03-25 | $27.92M derived: sum of 3 quarters · filed 2026-08-13 | $33.38M 10-K · filed 2026-03-25 |
| 2025-09-30 | $9.80M 10-Q · filed 2025-11-12 | $18.55M derived: sum of 2 quarters · filed 2026-08-13 | $24.01M 10-Q · filed 2025-11-12 | $28.34M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $8.75M 10-Q · filed 2026-08-13 | $14.21M 10-Q · filed 2026-08-13 | $18.54M derived: sum of 3 quarters · filed 2026-08-13 | $21.10M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $5.46M 10-Q · filed 2026-05-12 | $9.79M derived: sum of 2 quarters · filed 2026-05-12 | $12.35M derived: sum of 3 quarters · filed 2026-05-12 | $13.98M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $4.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $6.89M derived: sum of 2 quarters · filed 2026-03-25 | $8.51M derived: sum of 3 quarters · filed 2026-03-25 | $10.64M 10-K · filed 2026-03-25 |
| 2024-09-30 | $2.56M 10-Q · filed 2025-11-12 | $4.19M derived: sum of 2 quarters · filed 2025-11-12 | $6.31M 10-Q · filed 2025-11-12 | $8.54M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.63M 10-Q · filed 2025-08-13 | $3.75M 10-Q · filed 2025-08-13 | $5.97M derived: sum of 3 quarters · filed 2025-08-13 | $7.12M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $2.12M 10-Q · filed 2025-05-12 | $4.35M derived: sum of 2 quarters · filed 2025-05-12 | $5.49M derived: sum of 3 quarters · filed 2025-05-12 | $6.50M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $2.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $3.37M derived: sum of 2 quarters · filed 2025-03-31 | $4.37M derived: sum of 3 quarters · filed 2025-03-31 | $7.88M 10-K · filed 2025-03-31 |
| 2023-09-30 | $1.14M 10-Q · filed 2024-11-14 | $2.15M derived: sum of 2 quarters · filed 2024-11-14 | $5.66M 10-Q · filed 2024-11-14 | $12.04M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $1.01M 10-Q · filed 2024-08-08 | $4.52M 10-Q · filed 2024-08-08 | $10.90M derived: sum of 3 quarters · filed 2024-08-08 | $15.47M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $3.51M 10-Q · filed 2024-05-14 | $9.89M derived: sum of 2 quarters · filed 2024-05-14 | $14.47M derived: sum of 3 quarters · filed 2024-05-14 | $17.69M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $6.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $10.95M derived: sum of 2 quarters · filed 2024-04-01 | $14.18M derived: sum of 3 quarters · filed 2024-04-01 | $16.09M 10-K · filed 2024-04-01 |
| 2022-09-30 | $4.57M 10-Q · filed 2023-11-14 | $7.80M derived: sum of 2 quarters · filed 2023-11-14 | $9.70M 10-Q · filed 2023-11-14 | $12.55M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $3.23M 10-Q · filed 2023-08-14 | $5.13M 10-Q · filed 2023-08-14 | $7.98M derived: sum of 3 quarters · filed 2023-08-14 | $8.79M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $1.90M 10-Q · filed 2023-05-15 | $4.75M derived: sum of 2 quarters · filed 2023-05-15 | $5.56M derived: sum of 3 quarters · filed 2023-05-15 | $6.31M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $3.65M derived: sum of 2 quarters · filed 2023-03-08 | $4.41M derived: sum of 3 quarters · filed 2023-03-08 | $4.63M 10-K · filed 2023-03-08 |
| 2021-09-30 | $805.39K 10-Q · filed 2022-11-14 | $1.56M derived: sum of 2 quarters · filed 2022-11-14 | $1.78M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $754.30K 10-Q · filed 2022-08-12 | $973.89K 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |